RESUMEN
Puerarin (PUE) is a good candidate for treating stroke, but its low concentration in brain after administration limits its curative efficacy. The aim of the present work was to design and characterize PUE loaded poly(butylcyanoacrylate) nanoparticles (PBCN) coated with polysorbate 80 (Ps 80), and to evaluate the effect of PBCN on the permeability of PUE across the blood-brain barrier (BBB) and the effect of PUE loaded PBCN on the cerebral ischemia/reperfusion injury. PUE loaded PBCN were successfully prepared by anionic polymerization method with the mean particle size of 201.2 nm and the zeta potential of -7.72 mV. The in vitro release behavior of PUE from the nanoparticles showed a biphasic profile manner with an initial burst release followed by a sustained release. The results of pharmacokinetic and biodistribution to brain performed in mice after intravenous administration showed that the drug concentrations in blood and brain for PUE loaded PBCN were both greater than these for the free drug. Moreover, compared with free drug, the vein injection of PUE loaded PBCN exerted the better neuroprotective effect in rats with focal cerebral ischemic injury via significantly decreasing neurological deficit scores, increasing body weight, lowing brain water content, and reducing the infarct volume. The results indicated that this preparation may reduce the total dose required for the stroke therapy with concurrent reduction in dose related toxicity. All these findings suggest that PBCN could enhance the transport of PUE to brain and have a potential as a neuroprotective agent in the focal cerebral ischemic injury.
Asunto(s)
Isquemia Encefálica/tratamiento farmacológico , Isoflavonas/administración & dosificación , Nanopartículas/administración & dosificación , Fármacos Neuroprotectores/administración & dosificación , Daño por Reperfusión/tratamiento farmacológico , Animales , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/metabolismo , Isquemia Encefálica/metabolismo , Cianoacrilatos/química , Dextranos/química , Enbucrilato , Infarto de la Arteria Cerebral Media , Isoflavonas/química , Isoflavonas/farmacocinética , Ratones , Nanopartículas/química , Fármacos Neuroprotectores/química , Fármacos Neuroprotectores/farmacocinética , Permeabilidad/efectos de los fármacos , Polietilenglicoles/química , Polisorbatos/química , Glicoles de Propileno/química , Ratas , Ratas Wistar , Daño por Reperfusión/metabolismoRESUMEN
This study examined the effects of curcumin on the pharmacokinetic and pharmacodynamic properties of warfarin and clopidogrel in Wistar rats. Results showed that oral administration of curcumin at 25 mg/kg, 50 mg/kg, and 100 mg/kg for 7 days had no substantial effects on the pharmacodynamics of warfarin and clopidogrel in this animal model. However, oral administration of 100 mg/kg curcumin for 7 days significantly increased the AUC0-∞ and Cmax of the two drugs (by × 1.6 and × 1.5, respectively, for warfarin, and × 1.61 and × 1.81, respectively, for clopidogrel carboxylic acid). However, compared to warfarin alone, different doses of curcumin combined with warfarin had no effects on the prothrombin time in rats. Similarly, a combination of curcumin and clopidogrel had no significant effect on the maximum platelet aggregation rate of rats compared with the use of clopidogrel alone. This work demonstrated that preadministration of 100 mg/kg curcumin affected the pharmacokinetics of warfarin and clopidogrel but had no effect on pharmacodynamic parameters such as anticoagulation rate and antiplatelet aggregation.
Asunto(s)
Anticoagulantes/farmacocinética , Curcuma/química , Curcumina/farmacología , Inhibidores de Agregación Plaquetaria/farmacocinética , Ticlopidina/análogos & derivados , Warfarina/farmacocinética , Administración Oral , Animales , Anticoagulantes/sangre , Coagulación Sanguínea/efectos de los fármacos , Cromatografía Liquida , Clopidogrel , Interacciones de Hierba-Droga , Masculino , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/sangre , Distribución Aleatoria , Ratas , Ratas Wistar , Espectrometría de Masas en Tándem , Ticlopidina/sangre , Ticlopidina/farmacocinética , Warfarina/sangreRESUMEN
The study was carried out in the Wistar rats to investigate the effect of curcumin pre-treatment on the pharmacokinetics of the hypertension-treating drug losartan and its metabolite EXP3174 following single oral administration. In the treatment group, rats were gavaged with losartan 10 mg/kg after repeat oral doses of curcumin (100 mg/kg, for 7 d), while rats in the control group were administrated only with the same dose losartan. The results showed that curcumin significantly increased the plasma concentrations of losartan and its metabolite EXP3174. The present study implicated the existence of herb-drug interaction between curcumin and losartan, and further evaluation of the possible interaction during curcumin administration needs to be considered.
Asunto(s)
Antagonistas de Receptores de Angiotensina/farmacocinética , Antioxidantes/farmacología , Curcumina/farmacología , Imidazoles/sangre , Losartán/farmacocinética , Tetrazoles/sangre , Antagonistas de Receptores de Angiotensina/sangre , Animales , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Femenino , Losartán/sangre , Masculino , Ratas , Ratas Wistar , Espectrometría de Masas en TándemRESUMEN
The purpose of this study was to investigate the preparation and characteristics of curcumin phospholipid complex, including the effects of reaction time, reaction solvent, reaction concentration and reaction temperature. Preparation technology resulted in that 0.5 g curcumin and 10 g soy phospholipid dissolved in 100 mL anhydrous alcohol, were stirred 1 h in 50 degrees C waterbath, then steamed alcohol in decompression, collected solid residue and vacuum dried for 12 h. The physicochemical properties for the new complex including IR spectrometer, mass spectrograph and HNMR equipment were detected. As a result, the formation of the complex is based on the reaction between phospholipid polar group rounding phosphorus atom and curcumin. This result gave the evidence for the formation mechanism of phospholipid complex.
Asunto(s)
Curcuma/química , Medicamentos Herbarios Chinos/química , Fosfolípidos/químicaRESUMEN
The present study was designed to determine the effects of puerarin pre-treatment on the pharmacokinetics of the oral anticoagulant agent warfarin and the antiplatelet agent clopidogrel in rats. In the treatment group, rats was gavaged with warfarin or clopidogrel after repeated treatment with puerarin at intraperitoneal doses of 20, 60, or 200 mg·kg(-1) for 7 days, while rats in the control group were administrated only with the same dose warfarin or clopidogrel. Plasma samples were obtained at the prescribed times and analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). The results showed that rats treated with puerarin at all the test doses of 20, 60 and 200 mg·kg(-1) were found to affect the pharmacokinetics of warfarin, but not clopidogrel, suggesting a potential herb-drug interaction between puerarin and warfarin.
Asunto(s)
Anticoagulantes/farmacocinética , Isoflavonas/farmacología , Inhibidores de Agregación Plaquetaria/farmacocinética , Ticlopidina/análogos & derivados , Vasodilatadores/farmacología , Warfarina/farmacocinética , Animales , Cromatografía Liquida , Clopidogrel , Esquema de Medicación , Interacciones de Hierba-Droga , Inyecciones Intraperitoneales , Isoflavonas/administración & dosificación , Masculino , Ratas , Ratas Wistar , Espectrometría de Masas en Tándem , Ticlopidina/farmacocinética , Vasodilatadores/administración & dosificaciónRESUMEN
AIM: To establish a sensitive and rapid liquid chromatographic-tandem mass spectrometry (LC-MS/MS) method for the quantitative analysis of dehydrated puerarin in rat plasma, and its application for pharmacokinetic studies. METHODS: A plasma sample was pretreated by one-step protein precipitation by the addition of five volumes of methanol. The chromatographic separation was achieved on a Zorbax SB-C18 column (4.6 mm × 150 mm I.D. 5.0 µm, Agilent, USA) at 40 °C at a flow rate of 0.6 mL·min(-1) by an isocratic elution consisting of 10 mmol·L(-1) ammonium acetate in methanol and water containing 0.1% formic acid in a ratio of 20 : 80 (V/V). Detection was performed on a triple quadrupole mass spectrometer in multiple-reaction monitoring (MRM) mode. An atmospheric pressure chemical ionization (APCI) interface in positive ionization mode was used by monitoring the transitions from m/z 399.1â281.0 (dehydrated puerarin) and m/z 271.0â215.0 (internal standard, IS). RESULTS: Calibration curves were linear in the concentration range from 1.50 to 5400 ng·mL(-1), and the lower limit of quantification (LLOQ) was 1.50 ng·mL(-1) in rat plasma. The accuracy and precision values, which were calculated from three different sets of quality control samples analyzed in sextuplicate on three different days, ranged from 95.73% to 103.18%, and from 4.33% to 7.86%, respectively. CONCLUSION: The method was successfully applied to assess the pharmacokinetics of dehydrated puerarin after oral administration in rats.